244 related articles for article (PubMed ID: 22607183)
21. Low-intensity allogeneic hematopoietic stem cell transplantation for myeloid malignancies: separating graft-versus-leukemia effects from graft-versus-host disease.
Burroughs L; Storb R
Curr Opin Hematol; 2005 Jan; 12(1):45-54. PubMed ID: 15604891
[TBL] [Abstract][Full Text] [Related]
22. Hemopoietic cell transplantation for myelodysplastic syndromes.
Benesch M; Deeg HJ
Curr Hematol Rep; 2003 May; 2(3):209-16. PubMed ID: 12901342
[TBL] [Abstract][Full Text] [Related]
23. Induction chemotherapy followed by allogeneic HCT versus upfront allogeneic HCT for advanced myelodysplastic syndrome: A propensity score matched analysis.
Konuma T; Shimomura Y; Ozawa Y; Ueda Y; Uchida N; Onizuka M; Akiyama M; Mori T; Nakamae H; Ohno Y; Shiratori S; Onishi Y; Kanda Y; Fukuda T; Atsuta Y; Ishiyama K;
Hematol Oncol; 2019 Feb; 37(1):85-95. PubMed ID: 30370627
[TBL] [Abstract][Full Text] [Related]
24. Allogeneic hematopoietic cell transplantation: the state of the art.
Gyurkocza B; Rezvani A; Storb RF
Expert Rev Hematol; 2010 Jun; 3(3):285-99. PubMed ID: 20871781
[TBL] [Abstract][Full Text] [Related]
25. Which Patients Should Undergo Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes, and When Should We Do It?
Oran B
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S43-9. PubMed ID: 26297277
[TBL] [Abstract][Full Text] [Related]
26. Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome.
Kongtim P; Parmar S; Milton DR; Perez JMR; Rondon G; Chen J; Chilkulwar AR; Al-Atrash G; Alousi A; Andersson BS; Im JS; Hosing CM; Bashir Q; Khouri I; Kebriaei P; Oran B; Popat U; Champlin R; Ciurea SO
Bone Marrow Transplant; 2019 Jun; 54(6):839-848. PubMed ID: 30258129
[TBL] [Abstract][Full Text] [Related]
27. Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Scott BL; Pasquini MC; Logan BR; Wu J; Devine SM; Porter DL; Maziarz RT; Warlick ED; Fernandez HF; Alyea EP; Hamadani M; Bashey A; Giralt S; Geller NL; Leifer E; Le-Rademacher J; Mendizabal AM; Horowitz MM; Deeg HJ; Horwitz ME
J Clin Oncol; 2017 Apr; 35(11):1154-1161. PubMed ID: 28380315
[TBL] [Abstract][Full Text] [Related]
28. Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and concurrent lymphoid malignancy.
Zimmerman Z; Scott BL; Gopal AK; Sandmaier BM; Maloney DG; Deeg HJ
Bone Marrow Transplant; 2012 Jun; 47(6):804-9. PubMed ID: 21909142
[TBL] [Abstract][Full Text] [Related]
29. Allogeneic hematopoietic cell transplantation from alternative donors in children with myelodysplastic syndrome: is that an alternative?
Kalwak K; Wójcik D; Gorczyńska E; Toporski J; Turkiewicz D; Slociak M; Ussowicz M; Pajdosz K; Socha P; Chybicka A
Transplant Proc; 2004 Jun; 36(5):1574-7. PubMed ID: 15251388
[TBL] [Abstract][Full Text] [Related]
30. Viewpoint: What is the role of allogeneic haematopoietic cell transplantation in the era of reduced-intensity conditioning--is there still an upper age limit? A focus on myeloid neoplasia.
Finke J; Nagler A
Leukemia; 2007 Jul; 21(7):1357-62. PubMed ID: 17508002
[TBL] [Abstract][Full Text] [Related]
31. Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium.
Nemecek ER; Hilger RA; Adams A; Shaw BE; Kiefer D; Le-Rademacher J; Levine JE; Yanik G; Leung W; Talano JA; Haut P; Delgado D; Kapoor N; Petrovic A; Adams R; Hanna R; Rangarajan H; Dalal J; Chewning J; Verneris MR; Epstein S; Burroughs L; Perez-Albuerne ED; Pulsipher MA; Delaney C
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1651-1656. PubMed ID: 29753157
[TBL] [Abstract][Full Text] [Related]
32. The evolution of hematopoietic SCT in myelodysplastic syndrome.
Kindwall-Keller T; Isola LM
Bone Marrow Transplant; 2009 Apr; 43(8):597-609. PubMed ID: 19252532
[TBL] [Abstract][Full Text] [Related]
33. Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome.
Nakamura R; Rodriguez R; Palmer J; Stein A; Naing A; Tsai N; Chang K; Slovak ML; Bhatia R; Spielberger R; Kogut N; Pullarkat V; Kirschbaum M; Forman SJ; O'Donnell MR
Bone Marrow Transplant; 2007 Nov; 40(9):843-50. PubMed ID: 17724447
[TBL] [Abstract][Full Text] [Related]
34. Transplantation for myelodysplastic syndromes: who, when, and which conditioning regimens.
Saber W; Horowitz MM
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):478-484. PubMed ID: 27913519
[TBL] [Abstract][Full Text] [Related]
35. Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome.
Lee KH; Lee JH; Lee JH; Kim DY; Seol M; Lee YS; Kang YA; Jeon M; Hwang HJ; Jung AR; Kim SH; Yun SC; Shin HJ
Blood; 2011 Sep; 118(9):2609-17. PubMed ID: 21715313
[TBL] [Abstract][Full Text] [Related]
36. Allogeneic hematopoietic cell transplantation in patients age 60-70 years with de novo high-risk myelodysplastic syndrome or secondary acute myelogenous leukemia: comparison with patients lacking donors who received azacitidine.
Platzbecker U; Schetelig J; Finke J; Trenschel R; Scott BL; Kobbe G; Schaefer-Eckart K; Bornhäuser M; Itzykson R; Germing U; Beelen D; Ehninger G; Fenaux P; Deeg HJ; Adès L; ; ; ;
Biol Blood Marrow Transplant; 2012 Sep; 18(9):1415-21. PubMed ID: 22579634
[TBL] [Abstract][Full Text] [Related]
37. Positive impact of chronic graft-versus-host disease on the outcome of patients with de novo myelodysplastic syndrome after allogeneic hematopoietic cell transplantation: a single-center analysis of 115 patients.
Hiramoto N; Kurosawa S; Tajima K; Okinaka K; Tada K; Kobayashi Y; Shinohara A; Inoue Y; Ueda R; Tanaka T; Kim SW; Yamashita T; Heike Y; Fukuda T
Eur J Haematol; 2014 Feb; 92(2):137-46. PubMed ID: 24127668
[TBL] [Abstract][Full Text] [Related]
38. Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes.
Oran B; Popat U; Andersson B; Champlin R
Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2():S282-8. PubMed ID: 24290213
[TBL] [Abstract][Full Text] [Related]
39. The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation.
Solh MM; Solomon SR; Morris LE; Zhang X; Holland HK; Bashey A
Biol Blood Marrow Transplant; 2019 Mar; 25(3):606-612. PubMed ID: 30244109
[TBL] [Abstract][Full Text] [Related]
40. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders.
Laport GG; Sandmaier BM; Storer BE; Scott BL; Stuart MJ; Lange T; Maris MB; Agura ED; Chauncey TR; Wong RM; Forman SJ; Petersen FB; Wade JC; Epner E; Bruno B; Bethge WA; Curtin PT; Maloney DG; Blume KG; Storb RF
Biol Blood Marrow Transplant; 2008 Feb; 14(2):246-55. PubMed ID: 18215785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]